Immediate-release calcifediol reduces parathyroid hormone by clinically meaningful amounts (≥ 30%) only when administered at doses that both raise serum 25(OH)D to supra-physiological levels (> 100 ng/mL) and increase the risk of hypercalcaemia [29, 33–35]. This evidence concerns the gene PTH and Hypercalcemia.